Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split: ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...